Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

CERE - Cerevel Therapeutics Holdings, Inc.

IEX Last Trade
44.97
31.260   69.513%

Share volume: 0
Last Updated: Thu 01 Aug 2024 11:23:26 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%
$13.71
31.26
228.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
15.40%
1 Year
6.26%
2 Year
46.26%
Key data
Stock price
$44.97
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$39.83 - $44.99
52 WEEK CHANGE
$5.94
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
182.195 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: N. Anthony Coles
Region: US
Website: cerevel.com
Employees: 300
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Cerevel Therapeutics Holdings, Inc. engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist, and CVL-871, which is in Phase 2a clinical trial to treat dementia-related apathy.

Recent news